B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma
Phase I/II Study of Brentuximab Vedotin and Methotrexate/ L-asparaginase/ Dexamethasone (B-MAD) Chemotherapy in Patients With Newly-diagnosed Extranodal NK/ T-cell Lymphoma
Sponsor: Takeda
This PHASE1/PHASE2 trial investigates Extranodal NK/T-cell Lymphoma and is currently completed. Takeda leads this study, which shows 11 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2024 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Dec 2023 — May 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 6 earlier versions
-
Jun 2022 — Jun 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2021 — Jun 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE1_PHASE2
-
May 2019 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — May 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Takeda
- The Thai Lymphoma Study Group
For direct contact, visit the study record on ClinicalTrials.gov .